TrialClinical cancer research : an official journal of the American Association for Cancer Research2017

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Steven E Coutré et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.